** Shares of Grifols GRLS.MC jump 9% after the Spanish drugmaker reported H1 results ahead of expectations, boosted by 'strong momentum' in immunoglobulin and proteins business
** The company booked a net profit of 177 million euros ($204.63 million), up 392% year-on-year, well above 141.1 mln euros expected by Bloomberg consensus, Capital Market says
** It also posted a 10.7% rise year-on-year in its adjusted EBITDA to 876 mln euros, up from 858.1 mln euros forecasted by Bloomberg
** Immunoglobulin revenues grew by 12.0% cc in the second quarter of the year
** 'We consider Grifols' immunoglobulins revenue performance as a positive read-through for CSL as it highlights ongoing strength in the Ig market,' RBC analysts say
** Share price is at its highest in 1.6 years, outperforming the IBEX35 index .IBEX, which falls 0.6%
($1 = 0.8650 euros)
(Reporting by Mireia Merino)
((Mireia.Merino@thomsonreuters.com; Reuters Messaging: mireia.merino.thomsonreuters.com@reuters.net))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。